PCLUS 3-18 MN

PCLUS 3-18 MN is an experimental HIV vaccine candidate composed of synthetic peptides derived from the envelope glycoprotein gp120 of the HIV-1 MN strain. It has been investigated in clinical trials as a potential immunotherapeutic or prophylactic agent for human immunodeficiency virus (HIV) infection. The vaccine aims to elicit an immune response, particularly by inducing neutralizing antibodies and possibly cytotoxic T lymphocyte responses against HIV, thereby preventing or controlling infection. The "MN" designation refers to the specific clade B isolate of HIV-1 used as the antigen source for this formulation[6][9]. Clinical studies have evaluated its safety and immunogenicity in individuals with early-stage HIV infection[9].